Results: 80

    Guidelines on HIV self-testing and partner notification: supplement to consolidated guidelines on HIV testing services

    Since the release of the consolidated guidelines in 2015, new evidence has emerged. Consequently, in an effort to further support countries, programme managers, health workers and other stakeholders seeking to achieve national and international HIV goals, this 2016 update issues new recommendations and a...

    Updates on HIV and infant feeding: the duration of breastfeeding and support from health services to improve feeding practices among mothers living with HIV

    WHO guidelines on HIV and Infant Feeding in 2010 for the first time recommended the use of antiretroviral drugs to prevent postnatal transmission of HIV through breastfeeding. This resulted in a major change from an individualised counselling approach toward a public health approach regarding how materna...

    Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach

    These guidelines provide guidance on the diagnosis of human immunodeficiency virus (HIV) infection, the use of antiretroviral (ARV) drugs for treating and preventing HIV infection and the care of people living with HIV. They are structured along the continuum of HIV testing, prevention, treatment and car...

    Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations

    In this new consolidated guidelines document on HIV prevention, diagnosis, treatment and care for key populations, the World Health Organization brings together all existing guidance relevant to five key populations – men who have sex with men, people who inject drugs, people in prisons and other close...

    The use of lateral flow urine lipoarabinomannan assay (‎LF-LAM)‎ for the diagnosis and screening of active tuberculosis in people living with HIV: policy guidance

    Tests based on the detection of mycobacterial lipoarabinomannan (LAM) antigen in urine have emerged as potential point-of-care tests for tuberculosis (TB). LAM antigen is a lipopolysaccharide present in mycobacterial cell walls, which is released from metabolically active or degenerating bacterial cells ...

    Consolidated guidelines on HIV testing services

    The Consolidated guidelines on HIV testing services bring together existing guidance relevant to the provision of HIV testing services (HTS) and addresses issues and elements for effective delivery of HTS that are common in a variety of settings, contexts and diverse populations. In addition, this docume...

    Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV

    This early-release guideline makes available two key recommendations that were developed during the revision process in 2015. First, antiretroviral therapy (ART) should be initiated in everyone living with HIV at any CD4 cell count. Second, the use of daily oral pre-exposure prophylaxis (PrEP) is recomme...

    Consensus statement: recommendations for the management of metabolic bone disease in human immunodeficiency virus patients

    "OBJECTIVE: To provide practical recommendations for the evaluation and treatment of metabolic bone disease in human immunodeficiency virus (HIV) patients. PARTICIPANTS: Members of scientific societies related to bone metabolism and HIV: Grupo de Estudio de Sida (GeSIDA), Sociedad Española de Endocrino...

    The role of mathematical modelling in the development of recommendations in the 2013 WHO consolidated antiretroviral therapy guidelines

    AIDS; 28 (Suppl 1), 2014
    Despite the exponential growth in the literature on modelling and simulation studies of impact and cost-effectiveness in different aspects of healthcare, there is no clear consensus on the appropriate role of modelling in the development of recommendations in clinical guidelines. This is compounded both ...

    Hormonal contraceptive methods for women at high risk of HIV and living with HIV: 2014 guidance statement

    During 9–12 March 2014, WHO convened a meeting of the Guideline Development Group (GDG) comprising 52 individuals representing a wide range of stakeholders, for the purpose of reviewing, and where appropriate, revising its Medical eligibility criteria for contraceptive use, fourth edition (MEC) guidanc...